Novo Nordisk announced a substantial reduction in the list prices of its leading obesity treatment, Wegovy, across multiple Chinese provinces. Local procurement documents show the two highest monthly doses were cut by approximately 48%, bringing them to 987 yuan (roughly $141) and 1,284 yuan (about $183) per dose. This follows a prior November 2025 price adjustment of up to 37%. With semaglutide’s patent set to expire in China in March 2026, this defensive move aims to sustain patient access and adherence but carries direct pressure on the company’s revenue growth from one of its fastest‐growing markets.

Investors received a boost when Novo Nordisk secured FDA approval for the first oral formulation of Wegovy, marking the inaugural GLP-1 weight management pill on the U.S. market. This complements Rybelsus, its existing oral GLP-1 diabetes therapy, and could broaden patient uptake by eliminating injection barriers. Concurrently, Wegovy’s label has expanded to include metabolic dysfunction-associated steatohepatitis and chronic kidney disease in type 2 diabetes patients, with analysts forecasting an additional $1 billion in annual sales from these new indications.

Novo Nordisk’s leadership overhaul this year underscores investor impatience amid intensifying rivalry from Eli Lilly’s tirzepatide franchise and burgeoning domestic Chinese generics. Despite an 81.9% gross margin and a 3.36% dividend yield, the company’s share price has fallen more than 50% year-to-date, its worst performance since listing. With semaglutide patents lapsing globally by 2026, investors are keenly watching mid- to late-stage candidates such as CagriSema and the strategic balance between price concessions and long-term market share preservation.